Collectively, these findings highlight the viability of Doxorubicin, 5-Fluorouracil, and 2-Methylcholine as therapeutic candidates targeting CPXM1 in osteoporosis, warranting further preclinical and clinical investigations to assess their efficacy and safety in this context. This evidence concerns the gene CPXM1 and osteoporosis.